Saturday
07.20.2019
4:27 AM
Login form
Search
Calendar
Entries archive

My site

Main » 2018 » July » 20

Dubai, United Arab Emirates.-Thursday 19 July 2018 [ AETOS Wire ]

Burjeel Hospital was named the ‘2018 Private Tertiary Care Service Provider of the Year’ at Frost & Sullivan Middle East Best Practices Awards Banquet 2018 held at Atlantis, The Palm in Dubai.

Burjeel Hospital (A unit of VPS Healthcare) is a leading advanced tertiary care establishment in the UAE with multiple specialities ranging from maternity care, orthopedic, and paediatrics to cardiac treatment.  The hospital attributes its success to its expert healthcare staff along with the latest in healthcare infrastructure supported by SAP’s integrated patient record system such as PACS (picture archiving and communication system). Burjeel has also been recognised by virtue of its patient care in terms of its capabilities to provide international cuisines to cater to its multi-ethnic patients and hospital staff.

Mr. Amir Firdaus, Group CEO Burjeel, VPS Healthcare says &ldqu ... Read more »

Views: 38 | Added by: uaeonlinenews | Date: 07.20.2018

Trajenta® demonstrates long-term cardiovascular safety in adults with type 2 diabetes

INGELHEIM, Germany & INDIANAPOLIS, Ind.-Thursday 19 July 2018 [ AETOS Wire ]

(BUSINESS WIRE)-- CARMELINA®1 (CArdiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with type 2 diabetes at high vascular risk) met its primary endpoint, defined as time to first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke (3-point MACE), with Trajenta® (linagliptin) demonstrating similar cardiovascular safety compared to placebo. Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced today positive top-line results, which evaluated the impact of treatment with linagliptin vs. placebo on cardiovascular safety on top of standard of care.

The study included 6,979 adults with type 2 diabetes and high cardiovascular risk.1 The majority of patients also had kidney disease, an important risk factor for ... Read more »

Views: 44 | Added by: uaeonlinenews | Date: 07.20.2018 | Comments (0)

 Results showed a significant improvement in these measures: lower median number of sickle cell crises, fewer hospitalizations, lower cumulative days in hospital, and lower incidence of acute chest syndrome

 

TORRANCE, Calif.-Thursday 19 July 2018 [ AETOS Wire ]

(BUSINESS WIRE)-- VIEW E-MEDIA KIT – Emmaus Life Sciences, Inc. (Emmaus) announced today that the New England Journal of Medicine (NEJM) has published the results of its 48-week phase 3 clinical trial of Endari™ (L-glutamine oral powder) which supported the FDA approval in July 2017 to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older.

The article reports results that showed significantly fewer sickle cell crises in those receiving Endari compared to placebo by 25 percent; p=0.005 (median 3 vs. median 4) and significantly fewer hospitalizations by 33 percent; p=0.005 (median 2 vs. median 3). Additional findings ... Read more »

Views: 34 | Added by: uaeonlinenews | Date: 07.20.2018

Mesh allows each TS4 unit to act as a relay station for signals on a solar array and extend the wireless range with the recently announced TAP
       


LOS GATOS, Calif.-Thursday 19 July 2018 [ AETOS Wire ]

(BUSINESS WIRE)-- Tigo®, pioneer of the smart modular Flex MLPE platform, today announced the release of its new Mesh communication architecture. This state-of-the-art wireless technology directly translates to customer benefits – including simplifying the solar design process and accelerating the commissioning steps. The complete Tigo solution uses a simple yet powerful data collection technology that covers the widest ranges of residential & commercial installations at the lowest cost. With Mesh and the recently announced Tigo Access Point (TAP), customers eliminate the need to address any roof obstruction or orientation constraint. To learn more about Mesh and TAP, register for Tigo’s free, online we ... Read more »

Views: 31 | Added by: uaeonlinenews | Date: 07.20.2018 | Comments (0)


SCOTTSDALE, Ariz.-Thursday 19 July 2018 [ AETOS Wire ]

(BUSINESS WIRE)-- Universal Laser Systems (ULS) announces the addition of 3M™, Victrex® and Dexmet materials to its materials database, the most extensive repository of laser material processing parameters for materials in the range of 10 watts to 500 watts.

The 3M, Victrex and Dexmet materials new to the ULS materials database were specifically added for laser processing with the ULTRA and XLS platforms, suited for high accuracy and precision laser cutting, laser ablation and laser surface modification.

The materials include:

    3M™ Extreme Sealing Tape 4412N
    3M™ Thermally Conductive Silicone Interface Pad 5516
    Victrex® APTIV® PEEK Film
    Dexmet PolyGrid® 8PTFE10-125ST Expanded PTFE
    Dexmet MicroGrid® AL 25 Expanded Aluminum

Laser pr ... Read more »

Views: 35 | Added by: uaeonlinenews | Date: 07.20.2018 | Comments (0)

 Data to be discussed with global health authorities, including the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)

 

OSAKA, Japan-Thursday 19 July 2018 [ AETOS Wire ]

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited [TSE:4502] (“Takeda”) today announced top-line results from the VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational subcutaneous (SC) formulation of vedolizumab for maintenance therapy in adult patients with moderately to severely active ulcerative colitis (UC) who achieved clinical response* at week 6 following two doses of open-label vedolizumab intravenous (IV) induction therapy. In the primary endpoint of the trial, a statistically significant proportion of patients receiving vedolizumab SC beginning at week 6 and every two weeks following achieved clinical remission** at week 52 compared to placebo. The safety data were consistent with the known safety pro ... Read more »

Views: 49 | Added by: uaeonlinenews | Date: 07.20.2018